Case Details
- Citation: [2012] SGHC 253
- Title: Novartis AG and another v Ranbaxy (Malaysia) Sdn Bhd
- Court: High Court of the Republic of Singapore
- Date: 28 December 2012
- Case Number: Suit No 150 of 2011
- Tribunal/Court: High Court
- Coram: Lee Seiu Kin J
- Judgment reserved: Yes
- Plaintiff/Applicant: Novartis AG and another
- Defendant/Respondent: Ranbaxy (Malaysia) Sdn Bhd
- Parties (as described): Novartis AG and another — Ranbaxy (Malaysia) Sdn Bhd
- Legal Areas: Patents and inventions
- Statutes Referenced: Patents Act (Cap 221, 2005 Rev Ed); Rules of Court (Cap 322, R 5, 2006 Rev Ed); (background) Medicines Act (Cap 176, 1985 Rev Ed)
- Key Procedural Provisions: O 87A r 11(6) of the Rules of Court; s 83 and s 84 of the Patents Act
- Patent at Issue: Patent No SG120119 (“Patent”)
- Medicines Act mechanism (background): s 12A(3)(a) notices to commence action within 45 days
- Counsel for Plaintiffs: Tony Yeo, D K Rozalynne PG Dato Asmali and Dora Tay (Drew and Napier LLC)
- Counsel for Defendant: Daniel Koh (Eldan Law LLP) (instructed) and Andrew Quirk (foreign counsel from Mirandah Law LLP)
- Judgment Length: 19 pages, 10,337 words
- Cases Cited (as provided): [2012] SGHC 253 (self-citation in metadata); Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553; FE Global Electronics Pte Ltd v Trek Technology (Singapore) Pte Ltd [2006] 1 SLR(R) 874; Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429; Main-Line Corporate Holdings Ltd v DBS Bank Ltd [2012] 4 SLR 147; European Central Bank v Document Security Systems Incorporated [2007] EWHC 600; DSM NV’s Patent [2001] R.P.C. 25; G1/93, Advanced Semiconductor Products (EPO Enlarged Board of Appeal)
Summary
Novartis AG and another v Ranbaxy (Malaysia) Sdn Bhd concerned an application by the patent proprietor and its exclusive licensee for leave to amend patent claims in the context of Singapore’s patent enforcement framework triggered by regulatory “early warning” notices. The defendant, a pharmaceutical company, sought to import and market “Starval Tablets” in Singapore. Under the Medicines Act regime, the defendant had notified the plaintiffs that the intended products could potentially infringe the plaintiffs’ patent, and that the plaintiffs needed to commence proceedings within a prescribed period to preserve their rights.
The plaintiffs commenced an infringement suit and, in parallel, sought leave to amend the claims of Patent No SG120119. The amendments were aimed at enhancing clarity, reducing the number of claims, and distinguishing the claims from prior art relied upon by the defendant. The dispute narrowed at the hearing to whether amendments to specific claims (notably claims 1 and 5) were permissible under the Patents Act, particularly the prohibition on amendments that add “additional matter” to the patent specification as filed.
The High Court (Lee Seiu Kin J) applied the established “added matter” test derived from Bonzel (T) and endorsed in Singapore authorities. The court emphasised a strict comparison between what the original application disclosed (explicitly and implicitly) and what the amended patent would disclose, assessed through the eyes of the skilled addressee. The court’s reasoning focused on whether the proposed amendments merely clarified or limited the invention using information already disclosed, or whether they effectively introduced new technical subject matter not clearly and unambiguously derivable from the original filing.
What Were the Facts of This Case?
Novartis AG was the registered proprietor of Patent No SG120119, and the second plaintiff was its exclusive licensee. Ranbaxy (Malaysia) Sdn Bhd, the defendant, intended to import for marketing in Singapore pharmaceutical products known as “Starval Tablets.” The defendant’s proposed products related to the plaintiffs’ patent, and the plaintiffs alleged that if the products were imported and marketed, the patent would be infringed.
Crucially, the defendant was obliged under the Medicines Act to serve notices to the patent proprietor when applying to the Health Sciences Authority for product licences. These notices served an “early warning” function: they informed the plaintiffs that the defendant’s intended products could potentially infringe the patent, and that the plaintiffs should commence an action in the High Court within 45 days to assert their rights. The plaintiffs did commence the suit within the relevant timeframe, seeking declarations of infringement.
In its defence and counterclaim, Ranbaxy challenged the validity of the patent. The invalidity argument was grounded in anticipation by prior art. Two prior art documents were relied upon and were referred to in the judgment as DA1 and DA2. While the full anticipation analysis is not reproduced in the extract provided, the procedural posture is clear: the plaintiffs’ infringement claim was met with a validity challenge, and the plaintiffs sought to amend the claims to better align with the patent’s inventive contribution and to distinguish the claims from the prior art.
The plaintiffs’ amendment application sought leave to amend the patent claims under s 83 of the Patents Act and O 87A r 11(6) of the Rules of Court. The stated objectives were to enhance clarity, highlight the inventive contributions, reduce the number of claims, and further distinguish the claims from the matter disclosed in the prior art references relied upon by the defendant. At the hearing, counsel agreed that the real controversy concerned whether amendments to claims 1 and 5 were permissible; amendments to other claims were treated as consequential to those core changes.
What Were the Key Legal Issues?
The central legal issue was whether the proposed amendments to the patent claims would contravene the statutory limits on amendment. Under s 83 of the Patents Act, the court has discretion to allow amendments in infringement or revocation proceedings. However, that discretion is constrained by s 84(3), which provides that no amendment shall be allowed if it results in the specification disclosing “any additional matter” or if it extends the protection conferred by the patent. In the present application, only the “additional matter” limb was engaged.
Accordingly, the court had to determine whether the amended claims would disclose subject matter that was not clearly and unambiguously disclosed in the patent application as filed. This required a careful comparison between the original disclosure and the amended disclosure, assessed through the eyes of the skilled addressee. The question was not whether the amendment would be obvious or whether it would improve the patentee’s position; rather, it was whether the amendment introduced new technical information that the applicant had not originally disclosed.
A secondary, practical issue flowed from the parties’ agreement on the scope of the dispute: the court needed to focus on claims 1 and 5 and evaluate whether the specific changes proposed for those claims were permissible. The court also proceeded on certain factual assumptions that were not disputed: valsartan was an active agent for which a separate patent subsists; microcrystalline cellulose improved performance of valsartan when used in a certain dosage; crospovidone is a drug disintegrant; and the patent relates to delivery and absorption of valsartan rather than to the compound of valsartan itself.
How Did the Court Analyse the Issues?
Lee Seiu Kin J began by setting out the legal principles governing patent amendments. The court noted that the plaintiffs’ application was brought under s 83(1) of the Patents Act, which empowers the court to allow amendments to the specification in proceedings where validity is in issue. The court’s discretion, however, is subject to s 84(3). In particular, s 84(3)(a) prohibits amendments that result in the specification disclosing additional matter. This statutory prohibition reflects a policy that applicants should not be allowed to improve their position by adding technical content not originally disclosed, thereby undermining legal certainty for third parties.
To determine whether an amendment adds matter, the court adopted the test from Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553. The Bonzel test is structured as a three-step exercise: first, ascertain what the original application discloses, explicitly and implicitly, through the eyes of the skilled addressee; second, ascertain what the patent as granted (or, in the amendment context, the amended specification) discloses; and third, compare the two disclosures to decide whether any relevant subject matter has been added. The court stressed that the comparison is strict: subject matter will be added unless it is clearly and unambiguously disclosed in the application as filed.
The court then confirmed that the Bonzel test had been endorsed in Singapore decisions, including FE Global Electronics Pte Ltd v Trek Technology (Singapore) Pte Ltd [2006] 1 SLR(R) 874, Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429, and Main-Line Corporate Holdings Ltd v DBS Bank Ltd [2012] 4 SLR 147. The court further referenced European Central Bank v Document Security Systems Incorporated [2007] EWHC 600 to elaborate on key points relevant to the “added matter” inquiry. In particular, the court emphasised that the exercise is not an obviousness test; it is a disclosure test. A patentee cannot add matter merely because the skilled person would find it obvious to derive from the original filing.
Although the extract provided truncates the remainder of the judgment, the analytical framework is clear from the portion reproduced. The court’s approach would have required construing both the original application and the proposed amended claims, including the claims as part of the disclosure. The court would then compare the original and amended positions to see whether the amendments introduced new limitations, numerical ranges, or structural features that were not clearly and unambiguously derivable from the original specification. The court’s emphasis on “explicitly and implicitly” disclosed content indicates that the patentee could rely on what the skilled addressee would take for granted, but only where that content is truly part of the original disclosure.
In the present case, the amendments were directed to claim structure and numerical ranges relating to the composition of a compressed tablet comprising valsartan in free form and particular proportions of microcrystalline cellulose and crospovidone. Because the dispute focused on amendments to claims 1 and 5, the court’s analysis would necessarily have examined whether the specific compositional limitations in the amended claims were already disclosed in the application as filed, either directly or implicitly, and whether the amendments merely clarified the scope of the invention or instead introduced new subject matter.
What Was the Outcome?
The provided extract does not include the final dispositive orders. However, the judgment’s structure and the legal framework indicate that the court’s decision turned on whether the amendments to claims 1 and 5 would result in additional matter under s 84(3)(a). In such applications, the court typically grants leave if the amendments are within the original disclosure and refuses leave if the amendments go beyond what was clearly and unambiguously disclosed.
Practically, the outcome would determine whether the plaintiffs could proceed with infringement declarations on the basis of the amended claim set. If leave was granted, the amended claims would become the operative basis for assessing infringement and for testing validity against the prior art. If leave was refused, the plaintiffs would remain confined to the unamended claims, potentially affecting both the scope of protection and the viability of the infringement case.
Why Does This Case Matter?
This decision is significant for patent practitioners in Singapore because it reinforces the strictness of the “added matter” prohibition in s 84(3)(a) of the Patents Act. The court’s reliance on Bonzel and its endorsement in local jurisprudence underscores that amendments are not a vehicle for re-engineering the invention’s technical disclosure after filing. The strict comparison—through the skilled addressee’s eyes—protects legal certainty for third parties who rely on the content of the patent application as originally filed.
For pharmaceutical patent litigation, the case is also practically relevant. Claim amendments often involve reformulating dosage forms, excipient selections, and numerical ranges to better distinguish from prior art or to align with the patent’s inventive contribution. This judgment’s approach signals that even when amendments appear to “clarify” or “limit” the claim scope, the court will still scrutinise whether the amended technical features were disclosed in the original application. Numerical ranges and compositional limitations are particularly sensitive, because small changes can amount to new technical subject matter if not clearly and unambiguously disclosed.
Finally, the case illustrates how amendment applications interact with the Medicines Act regulatory notice regime. The procedural context—where a patent proprietor must act promptly after receiving regulatory notices—can create pressure to refine claims quickly. The court’s insistence on statutory compliance ensures that such refinements do not undermine the disclosure bargain that underpins patent law.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), ss 83 and 84(3)
- Rules of Court (Cap 322, R 5, 2006 Rev Ed), O 87A r 11(6)
- Medicines Act (Cap 176, 1985 Rev Ed), s 12A(3)(a) (background regulatory notice mechanism)
Cases Cited
- Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553
- FE Global Electronics Pte Ltd and others v Trek Technology (Singapore) Pte Ltd and another appeal [2006] 1 SLR(R) 874
- Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429
- Main-Line Corporate Holdings Ltd v DBS Bank Ltd [2012] 4 SLR 147
- European Central Bank v Document Security Systems Incorporated [2007] EWHC 600
- DSM NV’s Patent [2001] R.P.C. 25
- G1/93, Advanced Semiconductor Products (EPO Enlarged Board of Appeal)
Source Documents
This article analyses [2012] SGHC 253 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.